What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Patients will receive CTX-471 as an intravenous (IV) infusion every 2 weeks until disease progression or unacceptable toxicity.”In the company’s words, NCT07684170 on ClinicalTrials.gov
- Tested for
- Neuroendocrine Neoplasm, Neuroendocrine Carcinomas, Neuroendocrine Tumors
- Main trialPhase 2
- “This study will enroll patients with central lab confirmed NCAM (CD56 IHC) positive metastatic neuroendocrine neoplasms that have progressed after standard of care treatment. CTX-471 to be administered as an intravenous (IV) infusion at either 0.3 mg/kg or 0.6 mg/kg every 2 weeks until disease progression or unacceptable toxicity. The study will be conducted in two stages. In Stage 1, 18 patients will be accrued for each dose level. If there are less than 2 objective responses in these 18 patients at either dose level, the dose level will be stopped. Otherwise, an additional 22 patients will…”In the company’s words, NCT07684170 on ClinicalTrials.gov
Other drugs for Neuroendocrine Neoplasm
- CAM2029Camurus AB · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
Coming up1
- Sep 2028Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07684170
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Sep 2028 | Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms | |
| Phase 1Terminated | 21 May 2025 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026